Please login to the form below

Not currently logged in
Email:
Password:

Briviact

This page shows the latest Briviact news and features for those working in and with pharma, biotech and healthcare.

UCB’s antiepileptic drug gains new US indication

UCB’s antiepileptic drug gains new US indication

FDA approves Briviact as a monotherapy to treat POS. The US Food and Drug Administration (FDA) has approved UCB’s Briviact (brivaracetam) CV as a monotherapy treatment option for epilepsy patients ... Jeff Wren, executive vice president and head of

Latest news

  • SMC gives green light for BMS’ Opdivo SMC gives green light for BMS’ Opdivo

    2014. Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy

  • UCB bags FDA approval for epilepsy drug Briviact UCB bags FDA approval for epilepsy drug Briviact

    Billy Dunn, director of the FDA's division of neurology products, said Briviact provides a welcome new treatment option for epilepsy patients. ... The recommended starting dose of Briviact is 50mg or 100mg a day, with a maintenance dose of 50mg to 200mg.

  • UCB wins European approval for epilepsy drug Briviact UCB wins European approval for epilepsy drug Briviact

    Plans first launches within weeks. UCB has been granted approval in the EU for Briviact, a new epilepsy drug, and says it plans to start launches of the drug before the ... Briviact was submitted for approval in the US in January 2015 but remains under

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics